MARKET

HALO

HALO

Halozyme
NASDAQ

Real-time Quotes | Nasdaq Last Sale

19.07
-0.60
-3.03%
After Hours: 19.07 0 0.00% 16:53 01/24 EST
OPEN
19.75
PREV CLOSE
19.67
HIGH
19.91
LOW
19.05
VOLUME
1.48M
TURNOVER
--
52 WEEK HIGH
20.50
52 WEEK LOW
14.61
MARKET CAP
2.79B
P/E (TTM)
-69.5224
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of HALO and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

HALO News

  • The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares
  • Benzinga.01/17 13:07
  • The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves Into Clinics
  • Benzinga.01/16 12:22
  • The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integra Lifesciences Lowers Q4 Guidance
  • Benzinga.01/15 13:22
  • Halozyme Adds $150M to Buyback
  • Benzinga.01/14 13:11

More

Industry

Biotechnology & Medical Research
-2.64%
Pharmaceuticals & Medical Research
-2.00%

Hot Stocks

Name
Price
%Change

About HALO

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company's segment also includes research and development activities and product sales of Hylenex recombinant. The Company's development pipeline consists of clinical-stage product candidates in oncology. Its lead oncology program is PEGPH20 (polyethylene glycol (PEG)ylated recombinant human hyaluronidase), a molecular entity being developed for the systemic treatment of tumors, which accumulate HA. It is in Phase II and Phase III clinical testing for PEGPH20 in stage IV pancreatic ductal adenocarcinoma (Studies 109-202 and 109-301); Phase Ib clinical testing in non-small cell lung cancer (Study 107-201), and in Phase Ib clinical testing in non-small cell lung cancer and gastric cancer (Study 107-101).
More

Webull offers Halozyme Therapeutics, Inc. (HALO) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.